Pharmaceutical M&A came back with a bang during October, after a quiet September. Merck & Co (NYSE: MRK) and AbbVie (NYSE: ...

AstraZeneca showcased positive early data on three experimental weight-loss drugs at ObesityWeek, highlighting its oral GLP-1 ...

US biopharma Vertex Pharmaceuticals was trading nearly 2% higher during pre-market trading on Tuesday. This followed Vertex’s ...

Spanish drugmaker PharmaMar Group today said it has received a payment of $10 million from Janssen Products, a Johnson & ...

French biotech Transgene today revealed it has entered into a license agreement with Germany-based contract development and ...

US neuroscience-focused biopharma Neurocrine Biosciences presented new data from more than 300 patients diagnosed with tardive dyskinesia and treated with Ingrezza (valbenazine) capsules at the 2024 ...

European regulators will decide by December 6 whether Novo Holdings, the controlling shareholder of Danish pharma giant Novo ...

Memo Therapeutics, a privately-held Swiss biotech company translating unique responses into superior medicines to treat viral infections and cancer, has appointed a new chief development officer (CDO) ...

The US Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for donidalorsen, an ...

Disc Medicine today announced a successful End of Phase 2 with the US Food and Drug Administration (FDA) supporting the ...

US biopharma Kymera Therapeutics, which is developing a new class of small molecule medicines using targeted protein degradation (TPD), has announced an important update on its pipeline.

German biotech BioNTech saw its shares rise more than 3% to $114.98 pre-market today, as it reported financial results for the three months ended September 30, 2024, that beat expectations. Revenues ...